Tag Archives: GlaxoSmithKline

Relieve the Stress from Asthma Management with New MyAsthma App

NOTTINGHAM, 18-Apr-2017 — /EuropaWire/ — A new and unique smartphone app to help people with asthma manage their condition has been developed by lung experts at the Nottingham Respiratory Research Unit and the pharmaceutical company GlaxoSmithKline (GSK). The MyAsthma app has been launched … Read the full press release

GlaxoSmithKline welcomes Brian McNamara as CEO of GSK’s Consumer Healthcare division

LONDON, 29-Sep-2016 — /EuropaWire/ — GSK today announced that Brian McNamara, is appointed Chief Executive Officer (CEO) of GSK’s Consumer Healthcare division effective immediately. He succeeds Emma Walmsley who was last week appointed GSK CEO Designate succeeding Sir Andrew Witty as … Read the full press release

GlaxoSmithKline completes sale of remaining stake in Aspen Pharmacare Holdings Ltd at ZAR 300 per share

LONDON, 29-Sep-2016 — /EuropaWire/ — Further to the announcement by GlaxoSmithKline on 28 September 2016, GlaxoSmithKline has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd (“Aspen”) at a price of ZAR 300 per share (the … Read the full press release

GlaxoSmithKline intends to sell remaining stake in Aspen Pharmacare Holdings Ltd

LONDON, 29-Sep-2016 — /EuropaWire/ — GlaxoSmithKline announces that it intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd (“Aspen”). The disposal will be through a placing of ordinary shares in Aspen to institutional investors (the “Offering”). The Offering is … Read the full press release

Kuehne + Nagel to run the core business of transporting products from the raw materials supplier to trade customers for GlaxoSmithKline (GSK)

London / UK, Schindellegi / CH, 13-1-2016 — /EuropaWire/ — Kuehne + Nagel and GSK signed an end-to-end global logistics partnership until 2021 that will see Kuehne + Nagel run the core business of transporting products from the raw materials … Read the full press release

Urs Rohner to join GlaxoSmithKline’s Board as Non-Executive Director from 1 January 2015

LONDON, 9-10-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015. On appointment, Mr Rohner will also become a member of GSK’s Remuneration … Read the full press release

GlaxoSmithKline and Medicines for Malaria Venture start phase III global programme of tafenoquine for the treatment of Plasmodium vivax malaria

London, 29-4-2014 — /EuropaWire/ — GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine, an investigational medicine which is being developed for the treatment and … Read the full press release

GlaxoSmithKline’s Incruse® (umeclidinium) gets European Commission marketing authorisation as maintenance bronchodilator treatment of COPD

London, 29-4-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Now licensed across … Read the full press release

GlaxoSmithKline delivers Q3 core EPS of 28.9p (+16% CER) and dividend of 19p (+6%)

London, UK, 23-10-2013 — /EuropaWire/ — GSK announces Q3 core EPS growth of 16% and dividend of 19p Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies Pharma & Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by … Read the full press release

GlaxoSmithKline submitted NDA to US FDA for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler

London, UK, 23-10-2013 — /EuropaWire/ — GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler. The NDA … Read the full press release

GSK and Pfizer owned ViiV Healthcare announced US regulatory submission for STR combining dolutegravir with abacavir and lamivudine for people living with HIV

London, UK, 23-10-2013 — /EuropaWire/ — ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people living with HIV-1. This New Drug … Read the full press release